Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis

Journal of the Neurological Sciences

Volumn 245, Issue 1-2, 2006, Pages 177-181

  Porcel, J ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Anticholinesterasics; Cognitive impairment; Donezepil; Multiple sclerosis; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; HUMAN; LEWY BODY; MEMORY; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUMANS; MULTIPLE SCLEROSIS;

EID: 33646939813     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2005.07.021     Document Type: Article

References (22)

1. Fisher J.S. Cognitive impairment in multiple sclerosis. In: Cook S.D. (Ed). Handbook of multiple sclerosis. 3rd. edn. (2001), Marcel Dekker, New York 33-255
2. Bobholz J.A., and Rao S.M. Cognitive dysfunction in multiple sclerosis. A review of recent developments. Curr Opinion Neurol 16 (2003) 283-288
3. Rao S.M., Leo G.J., Bernardin L., and Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology 41 (1991) 685-691
4. Rao S.M., Leo G.J., Ellington L., Nauertz T., Bernardin L., and Unverzagt F. Cognitive dysfunction in multiple sclerosis: II. Impact on employment and social functioning. Neurology 41 (1991) 692-696
5. Spencer C.M., and Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 13 (1998) 391-411
6. McKeith I., Del Ser T., Spano P., Emre M., Wesnes K., Anand R., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356 (2000) 2031-2036
7. Werber E.A., and Rabey J.M. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108 (2001) 1319-1325
8. Kumar V., Anand R., Messina J., Hartman R., and Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 7 (2000) 159-169
9. Masanic C.A., Bayley M.T., VanReekum R., and Simard M. Open-label study of donepezil in traumatic brain injury. Arch Phys Med Rehabil 82 (2001) 896-901
10. Pozzilli C., Passafiume D., Bernardi S., Pantano P., Incoccia C., Bastianello S., et al. SPECT, MRI and cognitive functions in multiple sclerosis. J Neurol Neurosurg Psychiatry 54 (1991) 110-115
11. Paulesu E., Perani D., Fazio F., Comi G., Pozzilli C., Martinelli V., et al. Functional basis of memory impairment in multiple sclerosis: a [18F]FDG PET study. Neuroimage 4 (1996) 87-96
12. Leo G.J., and Rao S.M. Effects of intravenous physostigmine and lecithin on memory loss in multiple sclerosis: report of a pilot study. J Neurol Rehab 2 (1988) 123-129
13. Unverzagt F.W., Rao S.M., and Antuono P.G. Oral physostigmine in the treatment of memory loss in multiple sclerosis (MS). J Clin Exp Neuropsychol 131 (1991) 74
14. Parry A.M., Scott R.B., Palace J., Smith S., and Matthews P.M. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126 (2003) 2750-2760
15. Greene Y.M., Tariot P.N., Wishart H., Cox C., Holt C.J., Schwid S., et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 20 (2000) 350-356
16. Rorie K.D., Stump D.A., Jeffery D.R., and Winston Salem N.C. Effects of donepezil on cognitive function in patients with multiple sclerosis. Neurology 56 Suppl. 3 (2001) A99
17. Boscà I., Bueno A., Gadea M., Casanova B., and Coret F. Donepezile and cognitive impairment in multiple sclerosis: a double-blind pilot study. Mult Scler 10 Suppl. 2 (2004) S150
18. Decoo D., and on behalf of the MS Rehab Study Group. Effects of donepezil in multiple sclerosis: a single-centre trial. Mult Scler 10 Suppl. 2 (2004) S150
19. Krupp L.B., Christodoulou C., Melville P., Scherl W.F., MacAllister W.S., and Elkins L.E. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63 (2004) 1579-1585
20. Christodoulou C., Krupp L.B., Brook S., Dwyer M.G., Melville P., Scherl W.F., et al. Relation to cognitive dysfunction to multiple neuroimaging measures over 24 weeks. Neurology 64 Suppl. 1 (2005) S26003
21. Porcel J., Borràs C., Arévalo M.J., Sánchez A., Cucala M., Falip M., et al. Design of a clinical trial to study the efficacy and safety of Exelon® (rivastigmine) in multiple sclerosis patients with cognitive disorders. Mult Scler 9 (2003) S143
22. Rao S.M. White matter disease and dementia. Brain Cogn 31 (1996) 250-268